Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs BMS 599626 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Ambit Biosciences Corporation
- 22 Jun 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 23 Jan 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 16 Apr 2012 Planned end date changed from 1 Apr 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.